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Cardiomyopathy: Getting Bigger 
All the Time - Lessons Learned 




In 1990, John and Christine Seidman uncovered the genetic association between 
mutations in sarcomeric contractile proteins and hypertrophic cardiomyopathy. 
Since then, the increase in knowledge and understanding of this disease has 
increased exponentially. Although pathologies associated with the various cardio-
myopathies are vastly different, in some cases, the same proteins are causative, but 
with different genetic mutations. The focus of this article will be on hypertrophic 
and dilated cardiomyopathies, which are often caused by mutations in sarcomeric 
contractile proteins. Tropomyosin, a thin filament protein, serves as a paradigm to 
illustrate how different mutations within the same protein can generate the hyper-
trophic or dilated cardiomyopathic condition. As such, the significant advances in 
information derived from basic science investigations has led to the development of 
novel therapeutics in the treatment of these pathological diseases. This article will 
illustrate linkages which occur to bridge scientific advances to clinical treatments in 
cardiomyopathic patients.
Keywords: hypertrophic and dilated cardiomyopathy, tropomyosin
1. Introduction
Cardiomyopathies are diseases with primary defects associated with the 
structure and function of the heart. They are commonly classified into 5 different 
categories: hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), 
restrictive cardiomyopathy (RCM), arrhythmogenic right ventricular cardiomy-
opathy (ARVC), and left ventricular noncompaction (LVNC). HCM and DCM are 
the most common of the cardiomyopathies, with an incidence of 1:500 and 1:2500, 
respectively. Although there are variations in phenotypes and etiologies, there are 
also similar symptoms among the cardiomyopathies. For example, HCM, DCM, and 
RCM often present with signs and symptoms that are common in heart failure with 
reduced ejection fraction, including peripheral edema, fatigue, dyspnea on exer-
tion, syncope, and cardiac ischemia [1, 2]. The focus of this article will be on HCM 
and DCM, the two most common cardiomyopathies.
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2. Hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is defined as left and/or right ventricle 
hypertrophy in the absence of external load, and without chamber dilation. 
Interventricular septal thickening predominates and may cause left ventricular 
outflow tract obstruction and/or mitral valve dysfunction. Other common features 
include myocyte disarray, fibrosis, alterations in calcium sensitivity of myofila-
ments, and cardiac arrhythmias that may lead to premature sudden death and/or 
heart failure. Phenotypic expression is variable, with some genetically-identified 
HCM individuals dying in their late teens/early twenties, whereas others have a 
normal life span with minimal disability dependent upon the specific mutation 
within the affected gene. In addition, modifier genes and environmental factors can 
influence disease progression and phenotype.
The genes associated with HCM can be roughly divided into several distinct 
categories: (1) genes definitively established as causing HCM via large family 
pedigrees; (2) genes likely causing HCM via small family pedigrees; and (3) genes 
associated with HCM via small families and sporadic cases [3]. However, as more 
genetic information is obtained on incidence of diseases, these categorizations 
may become blurred. Usually, HCM is inherited as an autosomal dominant disease 
where a single missense point mutation in the affected gene is sufficient to cause the 
disease, although there is variability in the phenotype. This variability in phenotype 
is also manifest by the numerous different point mutations that occur within a 
specific gene; for example, the myosin heavy chain 7 (MYH7) R403Q mutation is 
associated with a severe pathological phenotype, whereas other MYH7 mutations, 
such as V606M, are relatively benign [4]. Studies also show that modifier genes 
and their polymorphisms, such as angiotensin II type 2 receptor and calmodulin, 
can influence the HCM pathology [4]. In addition, mutations that occur in differ-
ent HCM-causing genes have dramatically different pathologies, with some being 
severe and others being relatively benign.
The genes primarily associated with the HCM phenotype are sarcomeric con-
tractile protein genes associated with both thick and thin cardiac myofilaments, 
along with the Z discs (Table 1). There are over 1500 mutations in these genes 
that are associated with HCM. The pioneering studies that revealed the molecular 
genetic basis of HCM and its association with sarcomeric protein genes were 
conducted by Drs. Christine and Jonathan Seidman [5]. These initial studies led to 
the discovery that mutations within most of the thick and thin filament sarcomeric 
protein genes of the heart can cause HCM (Table 1). In the United States, the 
most common genes associated with HCM are β-myosin heavy chain (MYH7) and 
myosin-binding protein C (MYBPC3); other thick filament protein genes which 
cause HCM are the regulatory light chain (MLC2) and the essential light chains 
(MLC 1/3). Most MYH7 mutations occur in the globular head and hinge region of 
the myosin heavy chain, although mutations in the rod domain also cause HCM. 
Although most HCM mutations in the contractile protein genes are missense muta-
tions, there is a bias for insertion/deletion mutations and premature truncation 
mutations in the MYBPC3 gene; these insertion/deletion mutations often result 
in translational reading frame shifts which lead to premature stop codons with 
subsequent degradation of the mRNA by nonsense mediated decay mechanisms or 
degradation of a truncated polypeptide. Thin filament protein genes associated with 
HCM are α-tropomyosin (TPM1α), troponin T, I, and C (TNNT2, TNNI3, TNNC1), 
and cardiac actin (ACTC1). The muscle LIM protein CSRP3, found in the Z-disc, 
also is a causal gene for HCM. Interestingly, HCM mutations in cardiac troponin T 
often have a relatively mild pathological phenotype but can lead to sudden cardiac 
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Gene Protein Protein function Cardiomyopathy
MYH7 β-Myosin heavy chain ATPase activity and Force generation in 
sarcomere
HCM, DCM
MYH6 α-Myosin Heavy Chain Principle protein of the thick filament 
with low expression in adult human 
ventricles
HCM, DCM
MYL2 Regulatory myosin light 
chain
Binds myosin heavy chain HCM
MYL1/3 Essential myosin light 
chain
Binds myosin heavy chain HCM
ACTC1 Cardiac α-actin Principle component of the thin 
filament
HCM, DCM
TPM1 α-Tropomyosin Blocks myosin interaction with actin in 
sarcomere
HCM, DCM
TNNT2 Cardiac troponin T Holds troponin complex on tropomyosin HCM, DCM
TNNI3 Cardiac troponin I Inhibits actomyosin interaction HCM, DCM
TNNC1 Cardiac troponin C Binds calcium to regulate sarcomeric 
contraction
HCM, DCM
MYBPC3 Myosin binding  
protein C
Structure & Contraction in the 
sarcomere
HCM, DCM
TTN TItin Structural component of the sarcomere HCM, DCM
CSRP3 Cysteine-and  
glycine-rich protein 3
Muscle LIM protein located in the Z disc HCM, DCM
ACTN2 Actinin Attaches actin filaments to the Z lines 
in muscle
HCM, DCM
TCAP Tcap (telethonin) Capping protein for titin HCM, DCM
MYOZ2 Myozenin 2  
(calsarcin 1)
Tethers calcineurin to the Z disc via 
actinin
HCM
PLN Phospholamban Regulates calcium entry into the 
sarcoplasmic reticulum
HCM, DCM
LDB3 Lim domain binding 3 Stabilizes the sarcomere during muscle 
contraction
HCM, DCM
FHL1 Four-and-a-half LIM 
domains 1
Muscle development and cardiac 
hypertrophy
HCM
MYLK2 Myosin light chain 
kinase 2
Phosphorylates myosin light chain 2 HCM
NEXN Nexilin Actin binding protein, part of T-tubule 
complex and Z discs
HCM, DCM
JPH2 Junctophilin-2 Structural protein linking the plasma 
membrane with the sarcoplasmic 
membrane.
HCM
CASQ2 Calsequestrin 2 Calcium binding protein HCM
VCL Vinculin Cytoskeletal protein HCM, DCM
ANKRD1 Ankyrin repeat  
domain 1
Transcriptional repressor of cardiac 
genes
HCM, DCM
TRM63 Muscle ring finger 
protein
Involved in proteasome-ubiquitin 
system for protein degradation
HCM,
Table 1. 
Genes found to cause cardiomyopathies.
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death. Over the years, the identification and verification of many of these sarco-
meric genes with HCM has been primarily through large family pedigrees, and 
often confirmed through experimental animal systems.
In addition to those genes mentioned that have a strong association with causing 
HCM, there are other cardiac muscle protein genes that when mutated are likely 
candidates for HCM. These genes include four-and-a-half LIM domains 1 (FHL1), 
myozenin 2 (MYOZ2), phospholamban (PLN), titin (TTN), titin capping protein 
(TCAP), and muscle ring finger protein 1 (TRM63) (Table 1) [3, 6, 7]. Although 
some of these associated proteins are located in the sarcomere (titin, titin capping 
protein), others are found peripherally, such as phospholamban which is in the 
sarcoplasmic reticulum membrane, and myozenin 2, located in the Z disc. There 
are also genes that are associated with HCM but occur more sporadically [3, 6, 7]. 
Some of these proteins are associated with cardiac muscle, such as troponin C, 
myosin light chain kinase 2, actinin 2, vinculin, nexilin, α-myosin heavy chain, and 
Lim domain binding 3 protein; other proteins are found globally, such as caveolin, 
junctophilin-2, and calsequestrin (Table 1). The fact that a vast array of different 
genes encoding proteins with diverse functions can all trigger the HCM pathological 
response demonstrates a common end point in the development of cardiovascular 
disease. However, we must also consider HCM is a large phenotypic category and 
that with more detailed pathological and physiological analyses, an improved diag-
nostic system might be developed. This has already been demonstrated by the addi-
tion of other cardiomyopathic classifications, such as restrictive cardiomyopathy, 
storage and metabolic cardiomyopathies, dilated cardiomyopathy, arrhythmogenic 
right ventricular cardiomyopathy, and mitochondrial cardiomyopathy.
3. Dilated cardiomyopathy
Dilated cardiomyopathy (DCM) is defined as dilation of the left or both ven-
tricles that is not explained by coronary artery disease or abnormal loading of the 
heart. The cardiac enlargement occurs with either normal thickness or thinning of 
the ventricular walls and varying amounts of fibrosis. Oftentimes, DCM leads to 
heart failure with reduced ejection fraction, tachyarrhythmias, and increased risk 
of sudden death. All four cardiac chambers may be dilated with increased end-
systolic volumes in both ventricles. The incidence of DCM is less well defined, with 
numbers varying between 1/250 individuals to 1/2500 individuals [6, 7]. Some of 
this variability can be attributed to the increased number of causes associated with 
DCM which include familial, viral myocarditis, cardiac toxins (i.e. alcohol, cocaine, 
amphetamine, cancer chemotherapeutic agents), peripartum cardiomyopathy, and 
prolonged tachycardia-related cardiomyopathy.
The genes associated with familial DCM are numerous and varied in their 
function (Table 1); however, the most common mode of inheritance is autosomal 
dominant. Over 50 genes have been identified that are linked to familial DCM, 
which encode proteins in the sarcomeres, ion channels, cytoskeleton, nuclear 
envelope, and mitochondria [6, 7]. Familial DCM comprises 30–50% of the DCM 
population. There is also allelic heterogeneity with mutations occurring in multiple 
regions within a specific gene. In fact, many genes are associated with causing both 
DCM and HCM, dependent upon the specific mutation (Table 1).
Titin, lamin A/C, and β-myosin heavy chain account for >25% of genetically-
inherited DCM [7, 8]. Titin, the longest human protein, is composed of 34,350 
amino acids with a mass of 3,816,030 Da. This sarcomeric protein functions as a 
scaffold for both thick and thin filaments in striated muscle. Many of the DCM-
associated mutations in titin encode premature stop codons, resulting in truncated 
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forms of the protein. These truncations often map to the A band of the sarcomere, 
rather than the I band, and are associated with phenotypically mild DCM. Other 
titin mutations result in sarcomere instability, decreased binding to its cap-binding 
protein (TCAP), decreased binding to the Z-disc, and a decreased stretch response 
during sarcomere contraction.
Mutations in the lamin A gene account for approximately 6% of all DCM muta-
tions, and is oftentimes associated with a high incidence of sudden cardiac death 
[8]. Lamin proteins are associated with intermediate filaments which support the 
nuclear membrane, along with a role in chromatin structure and possibly gene 
transcription. Mutations in the lamin gene often lead to nuclear membrane dam-
age and/or chromatin disorganization and impaired gene transcription. Because 
of lamin’s diverse function, mutations lead to a wide variety of disease conditions, 
including premature aging and various myopathies, including DCM. In the heart, 
LMN A mutations often lead to dysrhythmias including sinus node and AV node 
dysfunction, atrial and ventricular fibrillation, and sudden cardiac death [8].
Mutations in genes involved in calcium/sodium handling are also associated 
with the onset of DCM. Phospholamban (PLN), a regulator of the sarcoplasmic 
reticulum Ca2+-ATPase pump, has several autosomal dominant mutations that 
result in DCM. In fact, the R14del mutation in PLN is associated with a founder 
effect in the Netherlands which results in a severe phenotype [9]. However, a milder 
DCM phenotype may also occur with the R14del mutation which demonstrates 
that modifying genes may play a role in the disease pathology. Another ion chan-
nel gene associated with DCM is SCN5A, a major sodium channel expressed in the 
heart. DCM mutations in this gene increase the risk for arrhythmias, whereas other 
SCN5A mutations result in channelopathies [6].
An examination of the genes associated with DCM and HCM clearly demon-
strates commonality in causing cardiomyopathies (Table 1). A clear example of this 
are the numerous sarcomeric protein genes, including titin, α- and β-myosin heavy 
chains, troponin T, I, and C, α-tropomyosin, α-actin, and titin capping protein, vin-
culin, desmin, and nexin (Table 1). There are also genes which appear more specific 
in causing only a single phenotype; genes associated with HCM are myosin light 
chain 2 and 1/3, myosin light chain kinase, and myozenin, whereas genes associated 
with only DCM include laminin α4, presenilin 1 and 2, and numerous others [6, 7]. 
The multitude of mutated genes that can result in DCM and HCM would infer that 
a continuum of phenotypes may exist for these cardiomyopathies dependent upon 
when the diseased heart is examined, which gene is mutated, where the mutation 
occurs, the type of mutation, associated modifying genes, and environmental influ-
ences. In fact, there are many cases where HCM hearts transition to DCM and heart 
failure as the disease progresses.
4. Tropomyosin and HCM
Tropomyosin (TPM) is an essential component of the sarcomeric thin filament 
that regulates muscle contraction and relaxation through its interactions with actin 
and the troponin complex. More specifically, striated muscle TPM, along with the 
troponin complex, regulates Ca2+-mediated actin-myosin crossbridges. As stated 
previously, the Seidman laboratory discovered through pedigree analysis and gene 
mapping that HCM was associated with mutations in myosin heavy chains [5]. The 
association of TPM with HCM was also reported by the Seidman laboratory in 1994 
which confirmed that HCM was a disease of the sarcomere and not solely confined 
to the thick filament [10]. In the United States, the percentage of HCM attributed 
to mutations in TPM is ~5%, with most of these cases exhibiting benign symptoms, 
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oftentimes first displayed in later years in life. However, in Japan, the phenotype is 
severe, but the incidence is low [11, 12]. Interestingly, TPM-associated cases are the 
most prevalent of all contractile proteins in causing HCM in Finland, with a severe 
pathological phenotype [13, 14]. The variability in incidence and pathology in the 
different populations is most likely due to allelic variants, modifier genes, founder 
effects, and environmental influences.
Mutations in the TPM1α gene are known to cause both HCM and DCM. There 
are at least 17 mutations that have been found to cause HCM and 11 mutations that 
can give rise to DCM (Table 2) [15, 16]. The striated muscle α-tropomyosin protein 
encodes 284 amino acids; this TPM isoform is the predominant TPM found in the 
adult human heart. The mutations that cause HCM are scattered throughout the 





























Adapted from [15, 16].
Table 2. 
TPM1α mutations that cause cardiomyopathy.
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gene/protein with a significant number located in the troponin-T binding regions, 
around amino acids 170–190 (Ile172Thr; Asp175Asn; Glu180Gly; Glu180Val; 
Leu185Arg; Glu192Lys) and amino acids 270–284 (Met281Thr; Ile184Val). A num-
ber of these mutations lead to a change in amino acid charge which may disrupt the 
dimerization of TPM with itself, or TPM’s interactions with actin and/or troponin 
T [17]. Also, most, if not all, of the HCM mutations occurring in thin filament sar-
comeric proteins lead to increased calcium sensitivity of the myofilaments, coupled 
with decreased systolic and diastolic cardiac function which may be causative for 
the development of this cardiomyopathy.
To understand the role of TPM in the development of HCM, our laboratory gen-
erated animal models of HCM. We produced the first in vivo transgenic mouse mod-
els expressing TPM with known HCM human mutations (Asp175Asn; Glu180Gln) 
[18–20]. Since there is a 100% amino acid sequence identity and comparable 
expression in the heart between mouse and human TPM, the mutations used in 
these transgenic mice reflect mutations and expression found in HCM patients. 
In addition, the exogenous cardiac-specific TPM transgene expression leads to a 
reciprocal decrease in endogenous TPM levels so that the total amount of TPM 
protein expression is unchanged in the hearts of these transgenic mice. Histological 
analyses demonstrate that the Asp175Asn transgenic mouse hearts show a moder-
ate hypertrophic response; in contrast, the Glu180Gln mice demonstrate a severe 
cardiac hypertrophy with significant fibrosis and atrial enlargement (Figure 1) 
[18–20]. Physiologically, mice from both models display significant systolic and 
diastolic dysfunction, coupled with increased sensitivity to Ca2+ in the myofila-
ments. The pathological and physiological disease state progresses rapidly in the 
HCM Glu180Gln mice, with the mice dying between 4 and 6 months postpartum.
Figure 1. 
HCM TPMα180 and NTG control hearts at the designated 1-month time intervals. (A) Cross-section of a  
three-month-old TPMα180 heart. (B and C) trichrome stain of left ventricular wall from control and 
TPMα180 hearts. B NTG control. C TPMα180. Note, blue fibrous staining in panel C.
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To understand the molecular mechanisms associated with the development 
of cardiomyopathy, we conducted a detailed comparative microarray analyses 
of hearts obtained from mild and severe HCM mice [21]. Ventricular tissue was 
obtained from 2.5-month-old TPMα175 and TPMα180 hearts, along with control 
(NTG) samples. Results show 754 genes (from a total of 22,600) were differentially 
expressed between the NTG and HCM hearts; 178 between NTG and TPMα175, 
and 388 between NTG and TPMα180. There are 266 differentially expressed genes 
between HCM TPMα175 and TPMα180. The genes that exhibit the largest increase 
in expression are associated with “secreted/extracellular matrix” category, and the 
most significant decrease in expression are in the “metabolic enzyme” category. 
This work illustrates the diverse array of genes that are activated and repressed dur-
ing the early signaling processes of mild and severe cardiac hypertrophy.
5. Rescue of HCM TPMα180 mice
The development of mouse models that mimic human HCM physiological and 
pathological conditions afford researchers the opportunity to examine various 
methods for rescuing these mice from cardiomyopathy. Studies demonstrate cardiac 
thin filaments with HCM mutations exhibit an increased sensitivity to calcium. As 
calcium is a prime regulator of muscle contraction, we hypothesized that by nor-
malizing myofilament calcium sensitivity, we could phenotypically rescue the HCM 
phenotype in our TPMα180 mice. Previously, we generated transgenic mice that 
exchanged the carboxyl terminal region of TPMα with that of TPMβ (Chi 1) [22]; 
these mice exhibit a decreased myofilament calcium sensitivity. By mating mice 
from the HCM TPMα180 with the Chi 1 mice, we tested the hypothesis that attenu-
ation of myofilament calcium sensitivity would modulate the severe physiological 
and pathological consequences of the HCM mutation. Results show the double-
transgenic mice “rescue” the hypertrophic phenotype by exhibiting a normal 
morphology with no pathological abnormalities, improved cardiac function, and 
normal myofilament calcium sensitivity [23, 24]. These results demonstrate that 
alterations in calcium response by modification of contractile proteins can prevent 
the pathological and physiological effects of this disease.
To extend our studies on rescuing HCM TPMα180 mice by modulation of 
cytosolic calcium, we crossbred the TPMα180 mice with phospholamban knockout 
mice (PLNKO) [25]. PLN is a Ca2+-handling protein that regulates calcium uptake 
into the sarcoplasmic reticulum. Previous studies show that PLNKO mice exhibit 
hypercontractility with no change in morphology or heart rate, no alterations in 
myofilament Ca2+ sensitivity, and myosin ATPase activity [26]. Results show that 
PLN ablation in the TPMα180 mice rescues cardiac function and morphological 
abnormalities for up to one year [25]. There was a reversal of the cardiac hypertro-
phy, fibrosis, and abnormal physiological function in these rescued mice. This work 
shows that by modulating sarcoplasmic reticulum calcium cycling, many of the 
deleterious aspects of HCM caused by a mutation in the thin filament protein TPM 
can be reversed.
We investigated whether oxidative myofilament modifications can reverse the 
diastolic dysfunction associated with HCM. The TPMα180 hearts display early 
signs of oxidative stress in the form of increased oxidative modifications of myosin 
binding protein C and activation of the MAPK signaling cascade. We hypothesized 
that treatment with the glutathione precursor N-acetylcysteine (NAC) may reverse 
the oxidative stress in the TPMα180 mice and improve the cardiomyopathic condi-
tion and diastolic dysfunction. To address this, NAC was administered for 30 days 
to control and TPMα180 mice. After NAC administration, the morphology, diastolic 
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dysfunction, and myofilament Ca2+ sensitivity of the TPMα180 mice was similar to 
controls, indicating that NAC had reversed the abnormal pathology and physiology 
associated with HCM [27]. These studies indicate that oxidative myofilament modi-
fications are an important mediator in diastolic function which can be of potential 
use in the treatment of HCM.
TPM is phosphorylated at a single site in the protein, located at the penultimate 
amino acid, serine 283. To address the significance of TPM phosphorylation, we 
generated transgenic mice where this serine residue is exchanged for alanine [28, 29]. 
These transgenic mice (S283A) exhibit a compensated hypertrophic response with 
significant increases in SERCA2a expression and phosphorylation of PLN. Having 
obtained these results, we postulated that decreasing TPMα phosphorylation may 
be beneficial in the context of a chronic, intrinsic stressor, such as HCM. To test this 
hypothesis, we generated mice expressing both the TPMα180 and S283A mutations 
and found the HCM phenotype was rescued [29, 30]. The double mutant transgenic 
mice exhibit no signs of HCM, displayed improved cardiac function, and have nor-
mal myofilament Ca2+ sensitivity. Changes in Ca2+ handling proteins may be respon-
sible for the improved functional performance found in the double transgenic hearts. 
Also, changes in local flexibility of the TPM molecule conferred by the replacement 
of the Serine residue with an Ala residue in the S283A mice, and the significant loss of 
phosphorylation, may be responsible for the restoration of TPM to proper flexibility. 
Structural alterations in actin-TnT-TPM protein interactions could play a vital role, 
however, the precise mechanism whereby decreased TPM phosphorylation rescues 
the HCM phenotype remains to be elucidated.
6. TPM and DCM
DCM, a disease often associated with heart failure, is characterized by depressed 
systolic function, cardiomegaly, and ventricular dilation. As mentioned previ-
ously, DCM is caused by a variety of conditions, including idiopathic, viral and 
cardiotoxins. Mutations in genes associated with DCM include sarcomeric proteins, 
the cytoskeleton, and the sarcolemma. Sarcomeric protein genes that harbor DCM 
mutations include α- and β-myosin heavy chain, myosin binding protein C, actin, 
TPM, troponin T, I, and C, desmin, vinculin, and muscle LIM protein (Table 1).
TPM mutations known to cause DCM are located throughout the TPM1 gene, 
from the 5′ to 3′ end of the associated transcript (Table 2). Some of the correspond-
ing amino acid changes are positioned in the inner regions of the TPM coiled-coil 
dimer where electrostatic charge interactions between specific amino acids may 
alter the TPM dimerization and/or binding to actin [31]. These non-conserved 
amino acid substitutions are thought to disrupt force transmission through the 
sarcomere leading to DCM.
To investigate the structural and physiological consequences of known DCM 
mutations in TPM with cardiac morphology and performance, we generated 
the first mouse model of a sarcomeric thin filament protein that leads to DCM 
(TPMαGlu54Lys) [32]. As with the transgenic HCM mice that were generated, 
the increase in transgenic TPM protein expression led to a reciprocal decrease in 
endogenous wildtype TPMα levels, with the total myofilament TPM levels remain-
ing unchanged. Also, since there is 100% amino acid identity between human and 
mouse TPM, the Glu54Lys DCM mutation is the same manifest in human DCM 
patients. Histological and morphological analyses of these transgenic mice revealed 
development of DCM with progression to heart failure, and death often ensuing 
by 6 months (Figure 2) [32]. Echocardiographic analyses confirmed the dilated 
phenotype of the heart with significant decreases in left ventricular fractional 
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shortening. There was also impaired systolic and diastolic function, coupled with a 
decreased Ca2+ sensitivity and tension generation in cardiac myofilaments. Results 
indicate the Glu54Lys mutation decreases TPM flexibility, which may influence 
actin binding and myofilament Ca2+ sensitivity. In summary, the pathological and 
physiological phenotypes exhibited by these mice are consistent with those seen in 
human DCM and heart failure patients.
Phosphorylation of cardiac sarcomeric and non-sarcomeric proteins play 
a major role in the regulation of the physiological performance of the heart. 
Phosphorylation of the thin filament proteins, such as troponin T and I, dramati-
cally affect myofilament Ca2+ sensitivity, along with systolic and diastolic function. 
Less is known about the physiological effect of TPM phosphorylation on cardiac 
performance. To address this issue, we generated transgenic mice having a phos-
phorylation mimetic substitution in the phosphorylation site of TPM (Ser283Asp) 
[33]. Previous work in our laboratory demonstrated that ablating the ability of 
TPM phosphorylation in transgenic mice (TPMαS283A) leads to a compensated 
physiological hypertrophy [28]. Our results show that high expression of the TPM 
Ser283Asp transgene leads to an increased heart:body weight ratio, coupled with 
a severe dilated cardiomyopathic phenotype resulting in death within 1 month 
of birth [33]. Moderate TPM Ser283Asp expression mice causes a mild myocyte 
hypertrophy and fibrosis, without affecting lifespan; physiological analysis revealed 
diastolic dysfunction, without changes in systolic performance. Surprisingly, there 
were no alterations in Ca2+ sensitivity of the myofibers, cooperativity, or calcium-
ATPase activity in the myofibers. This work revealed for the first time that constitu-
tive phosphorylation of TPM could result in a DCM phenotype with its severity 
dependent upon the extent of the posttranslational phosphorylation modification.
Studies demonstrate that during embryonic and fetal cardiogenesis, the murine 
heart expresses both TPMα and TPMβ isoforms, with the TPMα isoform being pre-
dominant in the adult heart [34–36]. During developmental, the ratio of TPMα:TPMβ 
changes from 5:1 to 60:1 in the embryonic to adult transition in the murine heart [36]. 
To address whether the TPMβ isoform could substitute for the TPMα protein, we 
generated transgenic mice that overexpressed TPMβ in the heart. Results show that 
Figure 2. 
Histopathology of DCM TPMα54 hearts. Masson trichrome staining of whole-heart longitudinal sections  
(i and ii) and cross sections (iii and iv) from 5-month-old NTG and moderate-copy TPMα54 mice; 
longitudinal sections (v and vi) and cross sections (vii and viii) from 1-month-old NTG and high-copy 
TPMα54 mice. Note the severe dilation of right and left ventricles in both the moderate and high-copy mice. 
Images in i through viii are all enlarged at the same magnification.
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with 60% TPMβ expression, there were no morphological changes in the heart [37]. 
However, there were physiological differences; although there were no systolic altera-
tions, diastole was impaired in both the time and rate of relaxation, coupled with an 
increase in myofilament Ca2+ sensitivity. Additional studies demonstrated that when 
the TPMβ transgene was expressed at high levels (80% TPMβ, 20% TPMα) in the 
heart, the mice developed a severe DCM phenotype and die with 14 days postpartum 
[38]. In these high expression TPMβ hearts, there is significant chamber dilation, 
thrombus formation in the atria and ventricles, and diastolic dysfunction.
An extension of the research on the high expression TPMβ mice entailed treat-
ment with cyclosporin and FK506, inhibitors of calcineurin. Calcineurin is a 
calcium-regulated phosphatase, which can initiate cardiac hypertrophy in hearts of 
transgenic mice that overexpress calcineurin [39]. Results show that treatment with 
cyclosporin or FK506 in various mouse models of cardiac hypertrophy, including 
the high expression TPMβ DCM mice, led to phenotypically rescued hearts [40]. 
This work suggests that in certain cases, inhibitors of calcineurin may play a poten-
tial therapeutic role in the treatment of heart disease.
There are 4 distinct tropomyosin genes, each one subject to alternative splicing 
which generates multiple isoforms of TPM. Our investigation into striated muscle 
TPM isoform content in the adult human heart found there is 92% TPMα1, 4% 
TPMβ, and 4% TPMα1κ [41]. TPMα1k is a unique human cardiac-specific TPM 
isoform which is normally not expressed in rodents [41, 42]. Additional studies show 
the associated protein is expressed and incorporated into organized myofibrils and 
that its level is increased in human dilated cardiomyopathy and heart failure patients 
[41]. To investigate the role of TPMα1κ in sarcomeric function, we generated trans-
genic mice overexpressing this cardiac-specific isoform. Incorporation of increased 
levels of TPMα1κ protein in myofilaments leads to DCM, coupled with systolic and 
diastolic dysfunction and decreased myofilament Ca2+ sensitivity [41, 43]. Additional 
biophysical studies demonstrate less structural stability and weaker actin-binding 
affinity of TPMα1κ protein compared with TPMα1. This functional analysis of 
TPMα1κ provides a possible mechanism for the consequences of the TPM isoform 
switch observed in DCM and heart failure patients.
7. Gene therapy approaches for repair of cardiomyopathies
Calcium plays a pivotal role in the regulation of muscle contraction and relax-
ation. As seen in the TPM mouse models, the HCM and DCM phenotypes all exhibit 
abnormalities in myofilament Ca2+ sensitivity and Ca2+ handling. As mentioned, 
when mice harboring a phospholamban (PLN) knockout are crossed with the HCM 
TPMα180 mice, the pathological phenotype is rescued from their offspring [25]. To 
extend our work, studies were conducted to more fully examine the role of cal-
cium and calcium-handling proteins in the development of HCM. To test whether 
improvements in the hypertrophic phenotype can be achieved through increased 
Serca2 expression, the HCM TPMα180 mice were treated with exogenous Serca2a, 
the protein involved in sequestering calcium from the cytoplasmic space into the 
sarcoplasmic reticulum [44, 45]. We implemented a gene transfer approach using 
an adenoviral vector to express Serca2a in HCM TPMα180 hearts. Results showed 
that injection of a single dose improved heart morphology and cardiac function. 
As the mice aged, there was a significant decrease in heart:body weight ratio, and a 
decrease in fibrosis when compared with controls. Additional work demonstrated 
that parvalbumin, a calcium buffer, may also play a role in ameliorating HCM; 
when parvalbumin transgenic mice were crossed with HCM TPM1α180 mice, there 
was improvement in cardiovascular performance [45, 46].
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With improvements in cardiac morphology and performance in the HCM and 
DCM mouse models that occur with modification in calcium handling proteins, 
therapeutic gene therapy trials in patients utilizing Serca2a expression as a poten-
tial treatment for cardiac disease were initiated. Using adeno-associated viruses 
to drive extended Serca2a expression, Phase 2 studies were conducted in patients 
with advanced heart failure [47, 48]. Results show there was a striking reduction in 
cardiovascular events that persisted through the 36 months of follow-up compared 
to patients who received the placebo. Additional work in this area is in progress.
Recently, investigators have examined the potential of the C-terminal end pep-
tide of troponin I as a novel reagent to selectively facilitate cardiac muscle relaxation 
[49]. This is a highly conserved protein fragment across numerous vertebrate species. 
Protein binding studies found that this terminal fragment retains its binding affinity 
for TPM similar to intact cardiac troponin I. Addition of this fragment to skinned 
cardiac muscle preparations reduces myofibril Ca2+ sensitivity without decreas-
ing maximum force production. Using this short peptide, studies were initiated to 
address whether it would be of therapeutic value in the treatment of HCM [50]. 
Recent work demonstrates that myofilament Ca2+ sensitivity isolated from TPMα180 
hearts exhibit a more normalized decrease in myofilament Ca2+ sensitivity when 
treated with the C-terminal troponin I fragment. This demonstrates the C-terminal 
peptide of troponin I as a potential therapeutic reagent for the treatment of diastolic 
dysfunction in the heart.
There is no scientific doubt that CRISPR-Cas9-base targeting has revolutionized 
how research is being conducted. With the ability to modify genomes, there is the 
potential to conduct precise gene-editing in animal models along with correcting 
human disease mutations. With respect to cardiomyopathic diseases, Ma et al. 
corrected a human heterozygous germline HCM mutation in the myosin binding 
protein C gene using the CRISPR-Cas9 system [51]. This targeting strategy was 
employed on preimplantation human embryos; following targeting, the embryos 
were genetically analyzed for correctly targeted nucleotide changes and then 
allowed to develop to the 8-cell stage. Results show that over 50% of blastomeres 
were correctly targeted, but used the wildtype allele as the correcting genetic 
template. This work demonstrates that CRISPR has the potential for usage as a 
corrective therapeutic system of heritable mutations; however, additional research 
needs to be conducted and ethical considerations need to be addressed.
8. Lessons learned from TPM
Many lessons have been learned about HCM and DCM in the examination and 
usage of TPM and associated mouse model systems [52, 53]. Multiple mutations 
within the TPM1α gene lead to HCM and DCM. Surprisingly, for both disease 
conditions, the mutations are scattered throughout the gene, and are not confined 
to one or two specific regions or domains. The severity of the disease phenotype 
appears dependent upon the specific mutation, modifying genes, and environmen-
tal factors. The genetic animal models of HCM and DCM TPM mutations accurately 
reflect the disease process with respect to structural and functional abnormalities 
as they occur in humans. For HCM, the thickening of the left ventricular wall and 
interventricular septum with significant fibrosis is pronounced in these animal 
models. For DCM, the thinning of the ventricular walls and dilation of the ventricu-
lar cavities reflect the pathological features observed in patients. For both HCM 
and DCM, the functional abnormalities in systole and diastole are similar to those 
experienced by patients. More importantly, these basic research studies have been 
translated into potential therapeutic modalities, especially for investigations into 
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the usage and modification of calcium-handling proteins as treatments of cardio-
vascular disease. Expansion of potential treatments utilizing phosphatases and 
kinases, along with sarcomeric protein peptides, may also prove beneficial for the 
treatment of specific cardiovascular conditions. An area of future expansion will 
be to focus on the identification and modification of protein expression for genes 
which are signaling agents for the development of cardiac HCM, DCM, and heart 
failure.
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